Earnings Insights · CI · Q3 FY2026

The Cigna Group Q3 2026 Earnings: Cigna Healthcare Offsets Pressure in Pharmacy Benefits

By AlgovestIQ ResearchPublished

Share

Read Cigna’s results announcement (Form 8-K, filed Nov 5, 2026)

Key earnings findings

Cigna (CI) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Cigna reported Q3 FY2026 revenue of $73.68B against the $72.64B analyst estimate, a 1.4% beat, and EPS of $7.98 against the $7.52 analyst estimate, a 6.1% beat.
  2. The Cigna Group raised its 2026 adjusted income from operations outlook to at least $30.60 per share, up $0.15 from its previous outlook.
  3. CI closed at $301.48 on Nov 5, 2026, down 1.3% from $305.41 on Nov 4, 2026, the last close before the results were released.

Sources: Cigna results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Cigna beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$73.68B
$72.64B
+1.4%
EPS
$7.98
$7.52
+6.1%
  • EPS has beaten the estimate in 7 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from 1.4% to 8.8%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

The Cigna Group reported third-quarter revenue of $73.7B, up 6% year over year, while adjusted income from operations rose modestly to $2.1B, or $7.98 per share. GAAP net income fell to $1.4B, or $5.47 per share, largely because the prior-year quarter included a gain on the sale of businesses.

The quarter reinforced the divergence inside Cigna’s portfolio. Cigna Healthcare delivered stronger earnings and modest margin expansion, while Evernorth’s Pharmacy Benefit Services business faced the anticipated effect of large contract renewals and investments behind its new Signature pharmacy-benefit model. Management raised its full-year adjusted EPS outlook by $0.15 to at least $30.60.

Earnings Snapshot

MetricReportedChange
Total revenue$73.7BUp 6% year over year
Adjusted revenue$73.8BUp 6% year over year
GAAP shareholders’ net income$1.4BDown from $1.9B
GAAP EPS$5.47Down from $6.98
Adjusted income from operations$2.1BUp from $2.1B
Adjusted EPS$7.98Up from $7.83
Evernorth adjusted revenue$63.8BUp 6%
Evernorth pre-tax adjusted income$1.8BDown 4%
Cigna Healthcare adjusted revenue$11.7BUp 9%
Cigna Healthcare pre-tax adjusted income$1.2BUp 15%
Cigna Healthcare medical care ratio85.0%Up from 84.8%
Debt-to-capitalization ratio41.8%Down from 44.9%

The Bigger Story

Cigna’s quarter showed that its growth profile is increasingly dependent on the resilience of Cigna Healthcare and Specialty and Care Services as Pharmacy Benefit Services enters a transition period.

Evernorth remains the larger revenue contributor, but its Pharmacy Benefit Services pre-tax adjusted income declined 22% year over year to $765M. Management attributed the decline to renewals and extensions of large client contracts, as well as investments needed to implement Signature, its planned fee-based and rebate-free pharmacy-benefit model.

The offset came from Cigna Healthcare, where pre-tax adjusted income increased 15% to $1.2B. Revenue grew 9%, primarily from premium rate increases designed to cover expected medical-cost trends, while stronger net investment income and operating efficiencies supported earnings.

The central strategic issue is whether Cigna can manage near-term pressure in Pharmacy Benefit Services while building a replacement growth path through Signature, specialty distribution, biosimilars, medical-benefit specialty drugs, and employer-market expansion.

Revenue and Operating Performance

Total revenue increased 6% to $73.7B, driven by growth in both Evernorth Health Services and Cigna Healthcare. Pharmacy revenue increased to $59.0B from $56.1B, premiums rose to $9.9B from $9.1B, and fees and other revenue increased to $4.5B from $4.4B.

Evernorth: Revenue Growth, but Uneven Earnings

Evernorth adjusted revenue rose 6% to $63.8B. Pharmacy Benefit Services revenue increased 9% to $37.3B, driven primarily by drug mix. That revenue growth did not translate into higher segment profit, reflecting the economics of contract renewals and the ongoing investment in the Signature transition.

Specialty and Care Services revenue rose only 1% to $26.5B, but pre-tax adjusted income increased 15% to $1.1B. Management said specialty distribution revenue grew strongly, while specialty pharmacy revenue declined because biosimilar and specialty-generic adoption reduced drug costs for clients and patients.

That distinction matters. Lower-cost drug substitution can restrain reported pharmacy revenue, but it can still improve specialty profitability if Cigna captures value through distribution, clinical services, and improved operating efficiency. Generic Revlimid penetration reached about 90%, according to management, while biosimilar adoption continued for products including Humira and Stelara.

Management also highlighted income from its investment in Shields Health as a contributor to Specialty and Care Services earnings growth. Shields’ underlying operating results are not consolidated into Cigna’s reported segment income.

Cigna Healthcare: Pricing and Efficiency Supported Growth

Cigna Healthcare adjusted revenue rose 9% to $11.7B, largely due to premium increases intended to cover higher expected medical costs. Pre-tax adjusted income rose 15% to $1.2B, helped by net investment income and operating efficiency.

Medical membership continued to edge higher. Total medical customers increased 2% from year-end 2025 to 18.5 million, with growth in Middle and Select markets partly offset by lower National Accounts membership. Management said Select, which serves employers with fewer than 500 employees, grew medical customers 5% year to date and reflected market-share gains.

The company also said its stop-loss business is performing in line with expectations. Cigna has been repricing that book to restore margins, and management expects additional margin recovery in 2027.

Profitability and Margins

Adjusted EPS increased 2% year over year to $7.98, despite adjusted income from operations remaining nearly flat at $2.1B. The per-share increase was supported by a lower share count: weighted average diluted shares declined to 263.8 million from 267.5 million a year earlier.

GAAP EPS declined 22% to $5.47. The primary factor was the absence of an after-tax gain on the sale of businesses recorded in the prior-year quarter. The current quarter also included $146M of after-tax special-item charges, or $0.55 per share.

Adjusted results excluded $449M of after-tax amortization of acquired intangible assets, $67M of after-tax net investment losses, and the special-item charges. Those special items included strategic optimization costs, litigation-related charges, integration and transaction costs, and deferred tax expenses.

At Evernorth, the key margin issue was Pharmacy Benefit Services. The business generated a 2.1% pre-tax adjusted margin, down from roughly 2.9% a year earlier, based on $765M of income on $37.3B of adjusted revenue. Specialty and Care Services produced materially stronger profitability, with pre-tax adjusted income rising faster than revenue.

Cigna Healthcare’s pre-tax adjusted margin improved to 10.2% from 9.7%. Its medical care ratio increased 20 basis points to 85.0%, reflecting U.S. employer business mix, partly offset by a lower ratio in the Individual and Family Plans business. The modest increase suggests medical costs remain elevated, but management said trend remains consistent with pricing assumptions.

The consolidated adjusted SG&A ratio increased to 4.7% from 4.6%. Cigna attributed the increase to investments and long-term growth initiatives, partly offset by operating efficiencies.

Demand, Customers and Pricing

Cigna’s customer metrics were mixed, reflecting expected client transitions and the loss of a government behavioral-health contract rather than broad deterioration in its medical franchise.

Total customer relationships declined 6% from year-end 2025 to 177.6 million. Pharmacy customers declined 5% to 117.7 million, which Cigna attributed to expected client transitions and lower membership among health-plan clients. Behavioral-care customers declined 19% to 23.0 million following the termination of a government contract, which management said had minimal impact on revenue and adjusted income.

The company’s medical customer base moved in the other direction, increasing 2% to 18.5 million. That growth is strategically more important than the headline decline in total customer relationships because medical customers support Cigna Healthcare’s premium, stop-loss, and integrated-benefit offerings.

Management also said Pharmacy Benefit Services retention is tracking in the high 90% range for the 2027 selling season. The company expects at least 2 million new Pharmacy Benefit Services customers in 2027, with new business written at targeted profit levels.

What is The Cigna Group’s guidance for full-year 2026?

The Cigna Group raised its 2026 adjusted income from operations outlook to at least $30.60 per share, up $0.15 from its previous outlook. The outlook includes the anticipated effects of share repurchases and dividends.

Management maintained its outlook for Evernorth pre-tax adjusted income from operations of at least $6.9B. It raised Cigna Healthcare pre-tax adjusted income from operations guidance by $50M to at least $4.6B.

Cigna also narrowed its full-year Cigna Healthcare medical care ratio outlook to 84.2%, plus or minus 25 basis points. The midpoint was unchanged, but the narrower range indicates greater confidence in expected medical-cost performance through year-end.

For 2027, management did not provide formal guidance but outlined the major earnings considerations. It expects at least 10% adjusted EPS growth from an estimated $30 adjusted EPS run rate for ongoing businesses. That starting point reflects an expected approximately $200M headwind from the company’s planned exit from the ACA exchange business, including lost contribution and remaining runoff or stranded costs.

Management expects Cigna Healthcare adjusted income to grow within its long-term 6% to 9% target range from reported 2026 results, and above the high end of that range after adjusting for the ACA exit. Specialty and Care Services income is expected to grow toward the low end of its long-term 8% to 12% range, as 2027 is expected to have fewer major biosimilar and specialty-generic launches.

Evernorth earnings are expected to rise by low single digits in 2027. Within that result, Pharmacy Benefit Services income is expected to decline by single digits because of industry-wide compression in rebate pools and lower employer coverage of GLP-1 drugs for weight management.

Balance Sheet, Cash Flow and Capital

Management said third-quarter operating cash flow was $2.6B and expects strong fourth-quarter cash flow, consistent with seasonal patterns in the prior two years.

The debt-to-capitalization ratio improved to 41.8% at September 30 from 43.0% at year-end 2025 and 44.9% a year earlier. Management remains on track to reach its long-term target of about 40% by year-end 2026, which could create more flexibility for capital deployment in 2027.

Cigna repurchased approximately 900,000 shares for about $250M during the third quarter. Through November 4, the company had repurchased 1.8 million shares for approximately $500M.

The company’s “Accelerate to One” modernization and productivity initiative is expected to generate $3B of gross run-rate savings by 2030. Management expects 70% to 80% of those savings to come from automation, process modernization, and workforce effectiveness, with the remainder from supplier and vendor management. Some savings will be reinvested in the business, limiting the amount that flows directly to earnings.

What Investors Should Watch

1. Pharmacy Benefit Services Profit Trends

Pharmacy Benefit Services revenue rose 9% in the quarter, but pre-tax adjusted income fell 22%. Investors should watch whether contract renewals, rebate-pool pressure, and lower GLP-1 coverage continue to compress earnings faster than growth in other Evernorth businesses can offset it.

2. Signature Implementation and 2028 Adoption

Cigna plans to introduce Signature to its fully insured Cigna Healthcare book on January 1, 2027, with broader Evernorth adoption expected to ramp in 2028. The key evidence of progress will be manufacturer and pharmacy-network contracting, client adoption, and the model’s effect on Pharmacy Benefit Services economics.

3. Cigna Healthcare Medical Costs and Stop-Loss Margins

The 85.0% third-quarter medical care ratio was consistent with management’s expectations, but medical cost trends remain elevated. Pricing discipline, reserve development, and stop-loss margin recovery will determine whether Cigna Healthcare can sustain its current earnings momentum.

4. Specialty Growth Beyond Biosimilar Tailwinds

Specialty and Care Services delivered 15% pre-tax income growth in the quarter, but management expects fewer material biosimilar and specialty-generic launches in 2027. Investors should watch whether specialty distribution, medical-benefit specialty products, and expanded infrastructure can sustain growth through that slower launch period.

5. ACA Exit Costs and Capital Deployment

Management estimates that exiting the ACA exchange business will create an approximately $200M headwind in 2027. The speed at which Cigna removes stranded costs, reaches its 40% debt-to-capital target, and expands buybacks will affect the bridge from 2026 results to its 2027 EPS-growth objective.

AlgovestIQ Takeaway

Cigna delivered a solid third quarter, but the investment story is more nuanced than the 6% revenue increase and raised EPS outlook suggest. Cigna Healthcare is performing well, supported by premium pricing, operating efficiency, investment income, Select-market membership growth, and improving stop-loss economics.

Specialty and Care Services also remains an important earnings engine. The segment’s income growth outpaced revenue growth as biosimilars, specialty generics, distribution, and clinical capabilities supported profitability. That business appears positioned for continued expansion, although management expects a less favorable new-product launch calendar in 2027.

The unresolved issue is Pharmacy Benefit Services. Cigna is intentionally accepting near-term pressure from large client renewals, industry rebate compression, lower GLP-1 coverage, and investments in the Signature model. Management expects the business to decline in 2027 before returning to growth over the subsequent years, making execution on the transition more important than near-term revenue growth alone.

The company’s raised 2026 outlook, lower leverage, and continued buybacks provide support for the near-term financial profile. Still, the core investment question is whether Cigna can replace mature PBM economics with durable growth from Signature, specialty distribution, integrated employer offerings, and productivity gains.

Evidence that Signature gains broad client adoption in 2028, Pharmacy Benefit Services margins stabilize, and Cigna Healthcare maintains medical-cost discipline would strengthen the long-term thesis. A deeper-than-expected decline in PBM profitability, weaker specialty growth after the biosimilar cycle slows, or difficulty removing ACA-related overhead would weaken it.

How did CI stock react?

CI closed at $301.48 on Nov 5, 2026, down 1.3% from $305.41 on Nov 4, 2026, the last close before the results were released.

SessionCloseChange
Nov 4, 2026 (before release)$305.41—
Nov 5, 2026$301.48-1.3%
Nov 6, 2026$293.59-3.9%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Cigna Q3 FY2026 earnings call transcript, as of Nov 5, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Cigna Form 8-K, Item 2.02 (SEC EDGAR), as of Nov 5, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Nov 5, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.